Vepdegestrant
Veppanu · PROTAC estrogen-receptor degrader
2026 first PROTAC ER degrader; no meaningful intrinsic renal signal.
Oral selective estrogen-receptor degrader (SERD)
Etcamah · CAMI
Oral selective estrogen-receptor degrader (SERD) · approved 2026 · 10 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An oral SERD switched in for the aromatase inhibitor when an ESR1 mutation appears in circulating tumor DNA. The kidney story belongs to its CDK4/6 partner: camizestrant does not block creatinine secretion, and its own arm had fewer creatinine rises than the comparator.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No renal lesion is attributed to camizestrant, and SERENA-6's comparator arm is what lets that be said rather than assumed. Every patient in the trial took a CDK4/6 inhibitor, and in the FDA label's laboratory table creatinine increased from baseline in 16% of patients on camizestrant with a CDK4/6 inhibitor (grade 3-4 0.6%; N=155) against 20% on an aromatase inhibitor with a CDK4/6 inhibitor (grade 3-4 1.3%; N=155) - lower on the camizestrant arm. The label also reports that camizestrant does not inhibit the tubular creatinine transporters OCT2, MATE1 or MATE2-K in vitro, so the creatinine rise clinicians see on this regimen is best read as the CDK4/6 inhibitor's. The label has no renal warning; its boxed warning is arrhythmia risk with QTc-prolonging drugs. SERENA-6 is published (Bidard, N Engl J Med 2025), but the renal laboratory rows come from the label.Source: No drug-attributable renal incidence: creatinine increased 16% all-grade / 0.6% grade 3-4 on camizestrant + CDK4/6 inhibitor (N=155) versus 20% / 1.3% on aromatase inhibitor + CDK4/6 inhibitor (N=155), FDA label SERENA-6 laboratory table
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Oral selective estrogen-receptor degrader (SERD) and complete estrogen-receptor antagonist that binds estrogen receptor alpha, including the ESR1-mutant receptor that confers resistance to aromatase inhibitors, and drives its degradation. Given as 75 mg orally once daily with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) that is continued at the dose the patient was already taking. The September 2026 approval is an accelerated approval based on progression-free survival measured from detection of the ESR1 mutation, and selection requires an FDA-authorized plasma test repeated every 3 months during first-line therapy.
Vasculature / Endothelium
Glomerular & peritubular capillaries
10 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1 , 5.2 , 7.1 ). Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of Torsades de Pointes. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently ( 5.1 , 7.3 ). Obtain ECG prior to initiation and monitor heart rate and QTc interval during treatment. Assess and correct electrolyte abnormalities prior to initiation and during treatment. Withhold ETCAMAH until resolution of QTc interval prolongation and resume or permanently discontinue ETCAMAH based on severity. ( 2.2 , 2.4 ) WARNING: ARRHYTHMIA RISK WITH CONCOMITANT USE OF QTc INTERVAL PROLONGING DRUGS See full prescribing information for complete boxed warning. • ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death ( 5.1 , 5.2 , 7.1 ). • Avoid concomitant use of ETCAMAH with…
Kidney rows of the label's dosage tables
From the ETCAMAH label (Sep 2026) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 14 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
14 total FAERS reports is below the 50 this atlas requires before quoting an odds ratio, so report counts are shown instead of RORs and none of these counts as a signal. A phenotype missing below was queried and never cleared even the nominal CI bar, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
14 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Camizestrant sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Veppanu · PROTAC estrogen-receptor degrader
2026 first PROTAC ER degrader; no meaningful intrinsic renal signal.
Orserdu · Oral selective estrogen-receptor degrader (SERD)
2023 oral SERD; nausea-dominant, minimal intrinsic nephrotoxicity.
Zenbexus · Cereblon E3 ligase modulator (CELMoD)
2026 first-in-class CELMoD; no attributable lesion (renal impairment 11% vs 8% on the comparator arm) but exposure rises 1.8x below eGFR 30 off dialysis.
Jideytro · ROS1-selective TKI
2026 TRK-sparing ROS1 TKI; no creatinine abnormality reached the label's >=20% lab-table cutoff — unlike the class's benign pseudo-AKI rise. Renally quiet so far.
HIF-2α inhibitor (investigational)
Trial-stage RCC HIF-2α inhibitor; renal profile being defined.
Modeyso · Imipridone (ONC201; DRD2/ClpP)
2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.